重大事件
即時報告
8-K
2026-08-10
Cogent Biosciences更新ATM融資計劃 新增最多4億美元股份發行額度
AI 繁中摘要
📌 Cogent Biosciences 提交 8-K：更新 ATM 融资計劃，新增最多 4 億美元股份發行額度
Cogent Biosciences, Inc.（納斯達克：COGT）於 2026 年 8 月 10 日向美國證交會（SEC）提交 8-K 申報文件，宣布就其現有的「按市價發售」（At-the-Market Offering, ATM）計劃提交新的招股章程補充文件，總發行額度上限為 4 億美元。💰
📄 主要內容摘要：
1️⃣ 融資安排背景
公司早於 2022 年 5 月 6 日與 Guggenheim Securities 簽訂銷售協議，其後於 2025 年 11 月 7 日修訂。根據該協議，公司可不時透過 Guggenheim Securities 作為銷售代理或主事人，按市場價格出售普通股。是次新補充招股章程乃根據《1933 年證券法》第 424(b) 條規則提交。
2️⃣ 發行規模與註冊聲明
是次申請發售的普通股總額上限為 4 億美元（約每股面值 0.001 美元），相關股份已納入公司於 2025 年 11 月 7 日提交並即時生效的 S-3ASR 自動貨架註冊聲明（檔案編號 333-291384）。
3️⃣ 法律意見
公司法律顧問 Gibson, Dunn & Crutcher LLP 已就股份發行合法性出具法律意見書，並作為附件 5.1 隨申報文件提交。
🧠 對投資者的潛在影響：
🔹 正面因素：此舉反映公司積極開拓融資渠道，為未來臨床試驗推進及營運資金需求提供財務彈性。S-3ASR 貨架註冊機制亦提升資金募集效率，有利公司在合適時機快速靈活集資。
🔹 潛在攤薄風險：ATM 融資通常會按市場價格分階段發行新股，意味著現有股東的持股比例可能被攤薄。投資者需留意公司實際發行股份的節奏與數量，以及資金用途是否具效益。
🔹 股價敏感度：ATM 計劃的啟動或會對短期股價構成一定壓力，特別是若市場預期公司將大規模發行股份。建議投資者密切關注公司未來季度業績及臨床數據公布，評估資金需求背後的原因及管理層的資本配置策略。
整體而言，是次申報屬常規融資文件的更新，短期內對公司基本面的直接影響有限，但長遠需觀察其實際發行規模及資金運用效率。📊
展開英文正文
8-K false 0001622229 0001622229 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2026 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38443 46-5308248 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 180 Third Avenue, 4th Floor Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (617) 945-5576 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. As previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. (the “Company”) entered into a Sales Agreement with Guggenheim Securities, LLC (“Guggenheim Securities”), as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at any time and from time to time through or to Guggenheim Securities, as sales agent or principal, at market prices by any method that is deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”). On August 10, 2026, the Company filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b) under the Securities Act with the U.S. Securities and Exchange Commission (the “SEC”) relating to the offer and sale of up to $400,000,000 of shares of Common Stock (the “Shares”) under the Sales Agreement. The Prospectus Supplement forms a part of the Company’s automatic shelf registration statement on Form S-3ASR (File No. 333-291384), which was filed with the SEC on November 7, 2025 and became automatically effective upon filing. Gibson, Dunn & Crutcher LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto. The Shares are registered pursuant to the Registration Statement and the base prospectus contained therein, and offerings of the Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy the Shares described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 5.1 Opinion of Gibson, Dunn & Crutcher LLP. 23.1 Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 10, 2026 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer and Corporate Secretary